X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abatacept (1333) 1333
science & technology (1227) 1227
humans (1205) 1205
life sciences & biomedicine (1203) 1203
immunoconjugates - therapeutic use (586) 586
female (554) 554
male (526) 526
antirheumatic agents - therapeutic use (516) 516
animals (495) 495
rheumatoid arthritis (474) 474
rheumatology (474) 474
arthritis, rheumatoid - drug therapy (473) 473
immunosuppressive agents - therapeutic use (446) 446
middle aged (388) 388
treatment outcome (369) 369
abatacept - therapeutic use (322) 322
adult (295) 295
immunology (294) 294
mice (260) 260
transplantation (249) 249
antibodies, monoclonal - therapeutic use (240) 240
aged (232) 232
ctla-4 antigen (227) 227
immunoconjugates (224) 224
rituximab (217) 217
tumor necrosis factor-alpha - antagonists & inhibitors (197) 197
t-lymphocytes - immunology (193) 193
antigens, cd (184) 184
abridged index medicus (175) 175
surgery (169) 169
t cells (169) 169
antirheumatic agents - adverse effects (166) 166
arthritis (150) 150
immunoconjugates - adverse effects (148) 148
antibodies, monoclonal, humanized - therapeutic use (144) 144
graft rejection - prevention & control (141) 141
drug therapy (133) 133
arthritis, rheumatoid - immunology (132) 132
methotrexate - therapeutic use (131) 131
drug therapy, combination (130) 130
rheumatoid factor (130) 130
analysis (129) 129
kidney transplantation (129) 129
pharmacology & pharmacy (129) 129
care and treatment (124) 124
time factors (120) 120
antigens, differentiation - therapeutic use (114) 114
musculoskeletal diseases (114) 114
immunoconjugates - pharmacology (112) 112
immunotherapy (108) 108
medicine & public health (107) 107
immunosuppressive agents - pharmacology (105) 105
severity of illness index (105) 105
infliximab (100) 100
research (99) 99
medicine, research & experimental (97) 97
research & experimental medicine (97) 97
methotrexate (96) 96
risk factors (96) 96
patients (94) 94
rats (94) 94
biological products - therapeutic use (93) 93
mice, inbred c57bl (93) 93
immunosuppression (92) 92
adalimumab (91) 91
etanercept (91) 91
immunosuppressive agents - adverse effects (91) 91
lymphocytes (90) 90
health aspects (87) 87
belatacept (86) 86
t-lymphocytes - drug effects (85) 85
graft rejection - immunology (83) 83
lymphocyte activation (83) 83
internal medicine (82) 82
clinical trials as topic (81) 81
mice, inbred balb c (81) 81
general & internal medicine (78) 78
tocilizumab (78) 78
cd28 antigens - immunology (77) 77
clinical trials (77) 77
immunoconjugates - administration & dosage (77) 77
lymphocytes t (76) 76
transplantation, homologous (76) 76
antigens (75) 75
antirheumatic agents (75) 75
graft survival - drug effects (75) 75
medicine, general & internal (74) 74
tumor necrosis factor-tnf (74) 74
adolescent (73) 73
immunosuppressive agents - administration & dosage (71) 71
antibodies, monoclonal, humanized (69) 69
graft survival - immunology (68) 68
retrospective studies (68) 68
antigens, differentiation - immunology (67) 67
abatacept - adverse effects (65) 65
quality of life (65) 65
child (63) 63
cyclosporine - therapeutic use (63) 63
double-blind method (63) 63
ctla-4 protein (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1553) 1553
French (20) 20
Japanese (20) 20
German (17) 17
Spanish (14) 14
Portuguese (6) 6
Italian (4) 4
Danish (3) 3
Hungarian (3) 3
Chinese (2) 2
Polish (2) 2
Czech (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Medical clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
The Medical clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 475 - 496
Over the past several decades, rheumatology has directed its focus to understanding and countering the immune dysregulation underlying autoimmune diseases with... 
Biologic response modifiers | Systemic lupus erythematosus | Vasculitis | Disease-modifying antirheumatic drugs | Biologics | Rheumatoid arthritis | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxychloroquine - therapeutic use | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Certolizumab Pegol | Rheumatic Diseases - drug therapy | Colchicine - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Cyclophosphamide - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Infliximab | Minocycline - therapeutic use | Immunoconjugates - therapeutic use | Antirheumatic Agents - therapeutic use | Rheumatic Diseases - immunology | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin G - therapeutic use | Rituximab | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Isoxazoles - therapeutic use | Adalimumab | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Tumor Necrosis Factors - antagonists & inhibitors
Journal Article
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2016, Volume 2016, Issue 6, pp. CD008334 - CD008334
Journal Article
BMJ Open, ISSN 2044-6055, 01/2017, Volume 7, Issue 1, pp. e014032 - e014032
... and severe HZ. The use of long-term medical records: a 14-year follow-up period (2001–2014) enhanced the statistical power and accuracy of this study. The present study... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxychloroquine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Herpes Zoster Ophthalmicus - epidemiology | Leflunomide | Methotrexate - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Case-Control Studies | Young Adult | Rituximab - therapeutic use | Time Factors | Arthritis, Rheumatoid - drug therapy | Adult | Female | Herpes Zoster - epidemiology | Odds Ratio | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Severity of Illness Index | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Adalimumab - therapeutic use | Abatacept - therapeutic use | Taiwan - epidemiology | Aged | Isoxazoles - therapeutic use | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Drugs | Codes | Biological products | Bacterial infections | Comorbidity | Rheumatology | Medical records | Infections | Epidemiology | Patients | Studies | Databases | Rheumatoid arthritis | Older people | Human immunodeficiency virus--HIV | Population | TNF inhibitors | Tumor necrosis factor-TNF | Health risk assessment | Viral infections | Index Medicus
Journal Article
Arthritis & rheumatology (Hoboken, N.J.), ISSN 2326-5191, 01/2019, Volume 71, Issue 1, pp. 5 - 32
Journal Article